摘要
由受体的过度表达或激活突变导致的表皮生长因子受体(EGFR)信号失调与肿瘤细胞的增殖,转移和生存相关。现已开发的EGFR已成为非–小细胞肺癌(NSCLC)的一个重要的治疗靶点,或作为非–小细胞肺癌(NSCLC)治疗的几个EGFR靶向药物,如酪氨酸激酶抑制剂(TKIs)和单克隆抗体(mAbs)。EGFR-TKIs吉非替尼 , 厄洛 替 尼 的 , 和 阿法替尼已经批准 用于 治疗 NSCLC晚期 ,这些药物的敏感性已被证明与表皮生长因子受体突变相关。各种单克隆抗体对表皮生长因子受体的临床前和临床研究中也进行了评价。特别是,III期临床试验结果显示,在化疗初治NSCLC晚期患者体内添加抗EGFR单抗西妥昔单抗或该药物与铂结合,临床显示对治疗非常有利。临床显著生存益处的抗EGFR单克隆抗体西妥昔单抗或试验一种铂化疗的晚期非小细胞肺癌患者钠ïVE添加。本文总结表皮生长因子受体靶向的单克隆抗体在治疗非小细胞肺癌过程中完成的和正在进行的临床试验结果。
关键词: 抗体,西妥昔单抗,表皮生长因子受体(EGFR),necitumumab,非小细胞肺癌,尼妥珠单抗,帕尼单抗。
图形摘要
Current Cancer Drug Targets
Title:Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Volume: 15 Issue: 9
Author(s): Masayuki Takeda and Kazuhiko Nakagawa
Affiliation:
关键词: 抗体,西妥昔单抗,表皮生长因子受体(EGFR),necitumumab,非小细胞肺癌,尼妥珠单抗,帕尼单抗。
摘要: Dysregulation of epidermal growth factor receptor (EGFR) signaling due to receptor overexpression or activating mutation is associated with cancer cell proliferation, metastasis, and survival. EGFR has become an important therapeutic target for non–small cell lung cancer (NSCLC), and several EGFR-targeted agents, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), have been developed. The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. Various mAbs to EGFR have also been evaluated in preclinical and clinical studies. In particular, phase III trials have shown a clinically significant survival benefit for addition of the anti-EGFR mAbs cetuximab or necitumumab to a platinum doublet in chemotherapy-naïve patients with advanced NSCLC. We here summarize the results of completed and ongoing clinical trials of EGFR-targeted mAbs for the treatment of NSCLC.
Export Options
About this article
Cite this article as:
Masayuki Takeda and Kazuhiko Nakagawa , Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer, Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/156800961509151110143001
DOI https://dx.doi.org/10.2174/156800961509151110143001 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry IL-13 and its Signal Pathway: Promising Targets in the Development of a Therapeutic Agent for Bronchial Asthma
Current Signal Transduction Therapy Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Nanotechnology Advances in Brain Tumors: The State of the Art
Recent Patents on Anti-Cancer Drug Discovery Ion Transporters in Brain Tumors
Current Medicinal Chemistry Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies
Current Neuropharmacology Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Overview of Base Excision Repair Biochemistry
Current Molecular Pharmacology